Virtu Financial LLC Acquires 10,923 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Virtu Financial LLC increased its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 1,058.4% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 11,955 shares of the medical research company's stock after purchasing an additional 10,923 shares during the period. Virtu Financial LLC's holdings in Thermo Fisher Scientific were worth $6,219,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of TMO. Howard Capital Management Group LLC lifted its position in shares of Thermo Fisher Scientific by 0.5% during the 3rd quarter. Howard Capital Management Group LLC now owns 54,575 shares of the medical research company's stock worth $33,759,000 after buying an additional 286 shares during the period. Principal Financial Group Inc. lifted its holdings in shares of Thermo Fisher Scientific by 22.1% during the third quarter. Principal Financial Group Inc. now owns 1,247,838 shares of the medical research company's stock valued at $771,876,000 after acquiring an additional 225,568 shares during the period. Intech Investment Management LLC grew its holdings in shares of Thermo Fisher Scientific by 8.8% in the 3rd quarter. Intech Investment Management LLC now owns 3,417 shares of the medical research company's stock worth $2,114,000 after purchasing an additional 275 shares during the last quarter. Landscape Capital Management L.L.C. acquired a new stake in shares of Thermo Fisher Scientific during the 3rd quarter worth about $235,000. Finally, Integrated Investment Consultants LLC boosted its position in Thermo Fisher Scientific by 34.2% in the third quarter. Integrated Investment Consultants LLC now owns 1,009 shares of the medical research company's stock valued at $624,000 after buying an additional 257 shares in the last quarter. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Remove Ads

Thermo Fisher Scientific Stock Down 0.2 %

Shares of TMO traded down $0.94 on Wednesday, hitting $513.40. The company's stock had a trading volume of 1,216,076 shares, compared to its average volume of 1,536,507. The company has a quick ratio of 1.29, a current ratio of 1.66 and a debt-to-equity ratio of 0.59. Thermo Fisher Scientific Inc. has a fifty-two week low of $493.30 and a fifty-two week high of $627.88. The firm's fifty day moving average price is $544.56 and its 200-day moving average price is $554.22. The firm has a market capitalization of $193.68 billion, a price-to-earnings ratio of 31.06, a P/E/G ratio of 2.99 and a beta of 0.79.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its quarterly earnings data on Thursday, January 30th. The medical research company reported $6.10 EPS for the quarter, topping analysts' consensus estimates of $5.94 by $0.16. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. On average, equities research analysts expect that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, April 15th. Shareholders of record on Friday, March 14th will be paid a $0.43 dividend. This is a boost from Thermo Fisher Scientific's previous quarterly dividend of $0.39. The ex-dividend date is Friday, March 14th. This represents a $1.72 annualized dividend and a yield of 0.34%. Thermo Fisher Scientific's payout ratio is presently 10.41%.

Insider Activity

In related news, CFO Stephen Williamson sold 9,825 shares of the stock in a transaction that occurred on Tuesday, February 4th. The stock was sold at an average price of $585.59, for a total transaction of $5,753,421.75. Following the completion of the transaction, the chief financial officer now directly owns 27,296 shares of the company's stock, valued at approximately $15,984,264.64. This represents a 26.47 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Marc N. Casper sold 10,000 shares of the company's stock in a transaction that occurred on Tuesday, March 4th. The stock was sold at an average price of $516.67, for a total value of $5,166,700.00. Following the sale, the chief executive officer now owns 115,174 shares in the company, valued at approximately $59,506,950.58. This represents a 7.99 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 23,900 shares of company stock worth $13,106,062 over the last ninety days. Insiders own 0.34% of the company's stock.

Analyst Ratings Changes

A number of research analysts have recently issued reports on the stock. Citigroup cut their target price on shares of Thermo Fisher Scientific from $650.00 to $570.00 and set a "neutral" rating for the company in a research note on Tuesday, March 4th. Morgan Stanley boosted their price objective on Thermo Fisher Scientific from $647.00 to $678.00 and gave the stock an "overweight" rating in a research note on Friday, January 31st. Scotiabank lifted their price target on Thermo Fisher Scientific from $605.00 to $650.00 and gave the company a "sector perform" rating in a report on Monday, February 3rd. StockNews.com raised shares of Thermo Fisher Scientific from a "hold" rating to a "buy" rating in a report on Tuesday, January 14th. Finally, Royal Bank of Canada set a $693.00 target price on shares of Thermo Fisher Scientific in a research report on Friday, January 31st. Four equities research analysts have rated the stock with a hold rating and nineteen have assigned a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $653.23.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.